Oncology Institute, Inc.: management transactions · United States · SEC (Form 4)

About Oncology Institute, Inc.

The Oncology Institute, Inc. (NASDAQ: TOI) is a U.S.-based oncology services company headquartered in Cerritos, California, in the United States, and listed on the NASDAQ market. Founded in 2007, the company has built a specialized care platform focused on cancer treatment and related complex conditions. For investors, TOI sits in the niche but strategically important intersection of community oncology, care coordination, and health-cost management within the highly fragmented U.S. healthcare system. The company’s business model is centered on delivering integrated oncology care through a network of clinics and physician offices, complemented by adjacent services designed to support treatment pathways. Its main operating lines include patient services, specialty pharmacy, and clinical trials and other ancillary services. The patient-services segment covers direct clinical care and associated reimbursement streams, while the specialty pharmacy business helps support the access, distribution, and coordination of select oncology therapies. Clinical-trial activity adds a further layer of capability and can strengthen physician engagement as well as the company’s relevance to advanced treatment protocols. TOI’s latest annual reporting indicates total operating revenue of about $502.7 million in 2025, up materially from the prior year, with growth driven primarily by patient services and specialty pharmacy. That performance suggests a company that has been scaling its operating base, although investors should continue to focus on margins, reimbursement dynamics, and execution quality. In a competitive sense, TOI differentiates itself by emphasizing an integrated, community-based oncology model rather than a hospital-centered structure. This can be attractive to payors and patients alike because it may improve access, continuity of care, and potentially cost efficiency. Geographically, TOI describes itself as a national platform, with meaningful clinic presence in California, Nevada, and Arizona, and broader reach across additional U.S. markets. That footprint is relevant because oncology care is highly local, relationship-driven, and dependent on referral networks. The company’s growth strategy therefore relies not only on clinical capacity, but also on commercial relationships, contract development, and market expansion. Recent SEC filings show a steady flow of Form 4 insider transaction disclosures, which is normal for a publicly traded healthcare company but still worth monitoring for sentiment and alignment signals. The annual report also highlights ongoing investments in referral management, new contract development, and call-center expansion, suggesting management remains focused on scaling the platform. Overall, TOI remains a growth-oriented U.S. healthcare company with exposure to clinical execution, payer economics, and the ongoing consolidation of outpatient oncology services on the NASDAQ market in the United States.